The role of GIP in α-cells and glucagon secretion
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) is an intestinally derived peptide that is secreted in response to feeding. The GIP receptor (GIPR) is expressed in many cell types involved in the regulation of metabolism, including α- and β-cells. Glucagon and insulin exert tremendous control over glucose metabolism. Thus, GIP action in islets strongly dictates metabolic control in the postprandial state. Loss of GIPR activity in β-cells is a characteristic of type 2 diabetes (T2D) which associates with reduced postprandial insulin secretion and hyperglycemia. Less is known about GIPR activity in α-cells or the control of glucagon secretion. GIP stimulates glucagon secretion in a glucose-dependent manner in healthy people, with enhanced activity at lower glycemia. However, GIP stimulates glucagon secretion even at hyperglycemia in people with T2D, suggesting that inappropriate GIPR activity in α-cells contributes to the pathogenesis of T2D. Here, we review the literature describing GIP action and GIPR activity in the α-cell, detailing the basic science that has shaped the view of how GIP regulates glucagon secretion. We also contrast the effects of GIP on glucagon secretion in healthy and T2D people. Finally, we contextualize these observations in light of recent work that redefines the role of glucagon in glucose homeostasis, suggesting that hyperglucagonemia per se does not drive hyperglycemia. As new medications for T2D that incorporate GIPR activity are being developed, it is clear that a better understanding of GIPR activity beyond the β-cell is necessary. This work highlights the importance of focusing on the GIPR in α-cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“However, it has become abundantly clear that GLP-1 is involved in many processes beyond stimulation of β-cell activity [3].”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes
Segerstolpe, Å., Palasantza, A., Eliasson, P., Andersson, E.-M., Andréasson, A.-C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, M. K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.020 · Cited by 1,550
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 2×
“In parallel, the development of multi-receptor agonists that target the GIPR have shown promising initial results in lowering body weight in patients with T2D [15], suggesting that including GIPR as a target in diabetes interventions may exploit new potential mechanisms beyond what is achieved by GLP-1R monoagonists.”
BackgroundPromotion of Insulin Secretion by Glucagon
Samols, E., Marri, G., & Marks, V. (1965) · The Lancet · doi:10.1016/s0140-6736(65)90761-0 · Cited by 521
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
DiGruccio, M. R., Mawla, A. M., Donaldson, C. J., Noguchi, G. M., Vaughan, J., Cowing-Zitron, C., van der Meulen, T., & Huising, M. O. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.04.007 · Cited by 353 · cited 1×
“The GIPR is expressed in all three major endocrine cells of the pancreatic islet: α-cells, βcells, and δ-cells [27].”
Background
Research works printed but not linked: 53
- Kreymann, 1987, Glucagon-like peptide-1 7-36: a physiological incretin in man, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
- Campbell, 2015, Islet alpha cells and glucagon--critical regulators of energy homeostasis, Nat. Rev. Endocrinol., 11, 329, 10.1038/nrendo.2015.51 · DOI · Paper page
- Holst, 2011, Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes, Diabetes Care, 34, S251, 10.2337/dc11-s227 · DOI · Paper page
- Zhou, 2007, Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets, Am. J. Physiol. Endocrinol. Metab., 293, E538, 10.1152/ajpendo.00070.2007 · DOI · Paper page
- Xu, 2007, Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes, Diabetes, 56, 1551, 10.2337/db06-1033 · DOI · Paper page
- Lefebvre, 2015, Inhibiting or antagonizing glucagon: making progress in diabetes care, Diabetes Obes. Metab., 17, 720, 10.1111/dom.12480 · DOI · Paper page
- Johnson, 1982, Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist, Science, 215, 1115, 10.1126/science.6278587 · DOI · Paper page
- Chepurny, 2019, Correction: nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP, J. Biol. Chem., 294, 8714, 10.1074/jbc.AAC119.009193 · DOI
- Capozzi, 2019, Beta Cell tone is defined by proglucagon peptides through cAMP signaling, JCI Insight, 4, 10.1172/jci.insight.126742 · DOI · Paper page
- Svendsen, 2018, Insulin secretion depends on intra-islet glucagon signaling, Cell Rep., 25, 1127, 10.1016/j.celrep.2018.10.018 · DOI · Paper page
- Rodriguez-Diaz, 2018, Paracrine interactions within the pancreatic islet determine the glycemic set point, Cell Metab., 27, 549, 10.1016/j.cmet.2018.01.015 · DOI · Paper page
- Zhu, 2019, Intra-islet glucagon signaling is critical for maintaining glucose homeostasis, JCI Insight, 5
- Capozzi, 2019, Glucagon lowers glycemia when beta-cells are active, JCI Insight, 5
- Chambers, 2017, The role of pancreatic preproglucagon in glucose homeostasis in mice, Cell Metab., 25, 927, 10.1016/j.cmet.2017.02.008 · DOI · Paper page
- Chia, 2009, Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes, Diabetes, 58, 1342, 10.2337/db08-0958 · DOI · Paper page
- Xin, 2016, Use of the Fluidigm C1 platform for RNA sequencing of single mouse pancreatic islet cells, Proc. Natl. Acad. Sci. U. S. A., 113, 3293, 10.1073/pnas.1602306113 · DOI · Paper page
- Ding, 1997, Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism, Diabetes, 46, 792, 10.2337/diab.46.5.792 · DOI · Paper page
- Hughes, 2018, Regulation of islet glucagon secretion: beyond calcium, Diabetes Obes. Metab., 20, 127, 10.1111/dom.13381 · DOI · Paper page
- Meier, 2007, Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects, Diabetologia, 50, 806, 10.1007/s00125-007-0598-z · DOI
- de Heer, 2008, Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas, Diabetologia, 51, 2263, 10.1007/s00125-008-1149-y · DOI · Paper page
- Sparre-Ulrich, 2017, GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release, Biochem. Pharmacol., 131, 78, 10.1016/j.bcp.2017.02.012 · DOI · Paper page
- Opara, 1991, Influence of gastric inhibitory polypeptide (GIP) and glucose on the regulation of glucagon secretion by pancreatic alpha cells, Regul. Pept., 32, 65, 10.1016/0167-0115(91)90035-F · DOI
- Tengholm, 2012, Cyclic AMP dynamics in the pancreatic beta-cell, Ups. J. Med. Sci., 117, 355, 10.3109/03009734.2012.724732 · DOI
- Franklin, 2005, Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release, Diabetes, 54, 1808, 10.2337/diabetes.54.6.1808 · DOI · Paper page
- Ishihara, 2003, Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells, Nat. Cell Biol., 5, 330, 10.1038/ncb951 · DOI · Paper page
- Elliott, 2015, Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic alpha-cell by lowering cAMP, Am. J. Physiol. Endocrinol. Metab., 308, E130, 10.1152/ajpendo.00344.2014 · DOI · Paper page
- Schuit, 1989, Sensitivity of rat pancreatic A and B cells to somatostatin, Diabetologia, 32, 207, 10.1007/BF00265096 · DOI
- Szecowka, 1982, Effect of GIP on the secretion of insulin and somatostatin and the accumulation of cyclic AMP in vitro in the rat, Acta Endocrinol (Copenh), 99, 416
- Moss, 2012, Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents, Diabetologia, 55, 3094, 10.1007/s00125-012-2663-5 · DOI · Paper page
- Rutter, 2009, Regulating glucagon secretion: somatostatin in the spotlight, Diabetes, 58, 299, 10.2337/db08-1534 · DOI
- Chia, 2014, GIP contributes to islet trihormonal abnormalities in type 2 diabetes, J. Clin. Endocrinol. Metab., 99, 2477, 10.1210/jc.2013-3994 · DOI · Paper page
- Lund, 2011, The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes, Am. J. Physiol. Endocrinol. Metab., 300, E1038, 10.1152/ajpendo.00665.2010 · DOI · Paper page
- Christensen, 2014, Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 99, E418, 10.1210/jc.2013-3644 · DOI · Paper page
- Finan, 2019, Repositioning glucagon action in the physiology and pharmacology of diabetes, Diabetes
- Christensen, 2015, Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes, Diabetes, 64, 72, 10.2337/db14-0440 · DOI · Paper page
- Christensen, 2010, Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes, Regul. Pept., 163, 96, 10.1016/j.regpep.2010.05.004 · DOI
- Stehouwer, 2018, Microvascular dysfunction and hyperglycemia: a vicious cycle with widespread consequences, Diabetes, 67, 1729, 10.2337/dbi17-0044 · DOI · Paper page
- Saxena, 2010, Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge, Nat. Genet., 42, 142, 10.1038/ng.521 · DOI · Paper page
- Speliotes, 2010, Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index, Nat. Genet., 42, 937, 10.1038/ng.686 · DOI · Paper page
- Lyssenko, 2011, Pleiotropic effects of GIP on islet function involve osteopontin, Diabetes, 60, 2424, 10.2337/db10-1532 · DOI · Paper page
- Arora, 2018, Association between genetic risk variants and glucose intolerance during pregnancy in north Indian women, BMC Med. Genomics, 11, 64, 10.1186/s12920-018-0380-8 · DOI
- Han, 2016, IGF2BP2 rs11705701 polymorphisms are associated with prediabetes in a Chinese population: a population-based case-control study, Exp. Ther. Med., 12, 1849, 10.3892/etm.2016.3554 · DOI
- Javorsky, 2016, A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins, Diabetes Obes. Metab., 18, 941, 10.1111/dom.12682 · DOI
- Berglund, 2016, Glucose-dependent insulinotropic polypeptide stimulates osteopontin expression in the vasculature via Endothelin-1 and CREB, Diabetes, 65, 239, 10.2337/db15-0122 · DOI · Paper page
- Garg, 2016, Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: an association analysis of polymorphisms and bone in young and elderly women, Bone Rep., 4, 23, 10.1016/j.bonr.2015.12.001 · DOI
- Ono, 2015, GIPR gene polymorphism and weight gain in patients with schizophrenia treated with olanzapine, J. Neuropsychiatry Clin. Neurosci., 27, 162, 10.1176/appi.neuropsych.13120389 · DOI
- Ahlqvist, 2013, Link between GIP and osteopontin in adipose tissue and insulin resistance, Diabetes, 62, 2088, 10.2337/db12-0976 · DOI · Paper page
- Sonestedt, 2012, Genetic variation in the glucose-dependent insulinotropic polypeptide receptor modifies the association between carbohydrate and fat intake and risk of type 2 diabetes in the Malmo Diet and Cancer cohort, J. Clin. Endocrinol. Metab., 97, E810, 10.1210/jc.2011-2444 · DOI · Paper page
- Ono, 2012, Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine, Pharmacogenom. J., 12, 507, 10.1038/tpj.2011.28 · DOI
- Joo, 2017, Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet-fed mice, Diabetes, 66, 868, 10.2337/db16-0758 · DOI · Paper page
- Beaudry, 2019, Physiological roles of the GIP receptor in murine brown adipose tissue, Mol. Metab., 10.1016/j.molmet.2019.08.006 · DOI · Paper page
- Ussher, 2018, Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction, Cell Metab., 27, 450, 10.1016/j.cmet.2017.11.003 · DOI
- Schiellerup, 2019, Gut hormones and their effect on bone metabolism. Potential drug therapies in future osteoporosis treatment, Front. Endocrinol. (Lausanne), 10, 75, 10.3389/fendo.2019.00075 · DOI
Cited by
Mechanisms controlling pancreatic islet cell function in insulin secretion
Campbell, J. E., & Newgard, C. B. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00317-7 · Cited by 629
Self-citationIncretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L., Encisco, S. E., Chazotte, B. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf1948 · Cited by 132
Self-citationEndosomal trafficking in metabolic homeostasis and diseases
Gilleron, J., & Zeigerer, A. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00737-9 · Cited by 57
Metadata
- Authors
- El, K., & Campbell, J. E.
- Venue
- Peptides
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 125
- Pages
- 170213
- ISSN
- 0196-9781 (ISSN-L)
- OpenAlex
- W2990930253
- Cited by
- 96
- References
- 29
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007012-41)
- National Institutes of Health
- American Diabetes Association (1-18-JDF-017)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of GIP in α-cells and glucagon secretion. https://app.cochat.ai/papers/10.1016/j.peptides.2019.170213
- The paper
- El, K., & Campbell, J. E. (2020). The role of GIP in α-cells and glucagon secretion. Peptides. https://doi.org/10.1016/j.peptides.2019.170213
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.